Bill Deegan is listed as a director on 4 SEC Form D filings by 1 issuer between Jun 2021 and Aug 2023: Cellebration Life Sciences, Inc. (Phoenix, AZ — biotechnology — 2021–2023; $2.8M reported sold to 63 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Anand Srivastava (4 shared filings), Deven Patel (4 shared filings) and Tim Kopatich (4 shared filings).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Bill. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 4 public filings for Bill Deegan and found 3 differences: Form D filed 16 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.